Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials

Hans-Peter Brunner-La Rocca, Luc Eurlings, A. Mark Richards, James L. Januzzi, Matthias E. Pfisterer, Ulf Dahlstrom, Yigal M. Pinto, Patric Karlstrom, Hans Erntell, Rudolf Berger, Hans Persson, Christopher M. O'Connor, Deddo Moertl, Hanna K. Gaggin, Christopher M. Frampton, M. Gary Nicholls, Richard W. Troughton

Research output: Contribution to journalArticleAcademicpeer-review

20 Citations (Scopus)
Original languageEnglish
Pages (from-to)1252-1261
JournalEuropean journal of heart failure
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 2015

Keywords

  • Heart failure
  • Biomarkers
  • Co-morbidity
  • Treatment response
  • Heart failure with preserved ejection fraction

Cite this

Brunner-La Rocca, H-P., Eurlings, L., Richards, A. M., Januzzi, J. L., Pfisterer, M. E., Dahlstrom, U., Pinto, Y. M., Karlstrom, P., Erntell, H., Berger, R., Persson, H., O'Connor, C. M., Moertl, D., Gaggin, H. K., Frampton, C. M., Nicholls, M. G., & Troughton, R. W. (2015). Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. European journal of heart failure, 17(12), 1252-1261. https://doi.org/10.1002/ejhf.401